Schizophrenia News and Research

Latest Schizophrenia News and Research

Adolescent brain remodeling goes awry in schizophrenia

A crucial reorganization process that occurs in the adolescent brain may be disturbed in those who go on to develop schizophrenia, a study suggests.

12 Dec 2013

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin, Inc. today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions.

12 Dec 2013

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Retrophin, Inc. today announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties.

12 Dec 2013

Researchers develop new screening tool to facilitate diagnosis of Autism Spectrum Disorder in adults

Researchers at Karolinska Institutet in Sweden have developed a new screening tool to facilitate the diagnosis of Autism Spectrum Disorder in adults. The test is presented in the scientific journal Molecular Autism and is unique in that researchers have, as part of their evaluation, compared the group diagnosed with Autism Spectrum Disorder with psychiatric patients.

12 Dec 2013

Schizophrenia treatment responses follow distinct trajectories

The positive and negative symptoms of schizophrenia generally change in parallel with each other, shows research, supporting the notion that the different symptom domains of the condition have a shared underlying pathology.

11 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Childhood trauma linked to poor social functioning in adult psychosis

Adults with first-episode psychosis who report childhood trauma tend to have poorer social functioning than those without such a history, a prospective study has shown.

10 Dec 2013

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Repetitive transcranial magnetic stimulation uses a non-invasive and relatively painless tool to stimulate the human brain in vivo using very strong, pulsed magnetic fields. It is also used to explore and elucidate neocortical functions and treat neuropsychiatric disorders.

9 Dec 2013

Research explores epigenetic effects that contribute to psychiatric disorders in offspring

Advanced paternal age has been associated with greater risk for psychiatric disorders, such as schizophrenia and autism. With an increase in paternal age, there is a greater frequency of certain types of mutations that contribute to these disorders in offspring.

9 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

Heptares starts HTL9936 Phase 1 study for improving cognitive function in Alzheimer's patients

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.

9 Dec 2013

Brain network disruption crosses psychosis diagnostic boundaries

Disruption of cortical information processing occurs in patients with psychosis regardless of whether they have a psychotic or affective diagnosis, research shows.

6 Dec 2013

Study reports new links between brain cell activity and choices where two options have equal appeal

Life presents us with choices all the time: salad or pizza for lunch? Tea or coffee afterward? How we make these everyday decisions has been a topic of great interest to economists, who have devised theories about how we assign values to our options and use those values to make decisions.

6 Dec 2013

Researchers identify gene involved in building circuitry that relays signals via brain

Using a powerful gene-hunting technique for the first time in mammalian brain cells, researchers at Johns Hopkins report they have identified a gene involved in building the circuitry that relays signals through the brain.

5 Dec 2013

Cognitive performance in psychosis has roots in childhood

The cognitive performance of patients with first-episode psychosis is not related to how long psychosis or other psychiatric symptoms have remained untreated, say researchers.

5 Dec 2013

Social defeat links past trauma to current psychosis

The feeling of social defeat may be responsible for the link between childhood trauma and psychosis, research suggests.

3 Dec 2013

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Childhood asthma, eczema linked to adolescent psychotic experiences

UK research indicates that children with asthma and eczema are significantly more likely to have psychotic experiences during adolescence, boosting a previously reported relationship between schizophrenia and atopic disorders.

28 Nov 2013

Substance use does not predict schizophrenia self-harm, violence

Substance misuse, although common among people with schizophrenia, does not heighten their risk for self-harm or violence, study findings show.

28 Nov 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

Adolescent brain remodeling goes awry in schizophrenia

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Researchers develop new screening tool to facilitate diagnosis of Autism Spectrum Disorder in adults

Schizophrenia treatment responses follow distinct trajectories

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

GW Pharmaceuticals receives U.S. patent for treating glioma

Childhood trauma linked to poor social functioning in adult psychosis

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Research explores epigenetic effects that contribute to psychiatric disorders in offspring

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Heptares starts HTL9936 Phase 1 study for improving cognitive function in Alzheimer's patients

Brain network disruption crosses psychosis diagnostic boundaries

Study reports new links between brain cell activity and choices where two options have equal appeal

Researchers identify gene involved in building circuitry that relays signals via brain

Cognitive performance in psychosis has roots in childhood

Social defeat links past trauma to current psychosis

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Childhood asthma, eczema linked to adolescent psychotic experiences

Substance use does not predict schizophrenia self-harm, violence

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Schizophrenia News and Research

Latest Schizophrenia News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in